Cancer antigen 125 - Revision history

Michael: /* See also */

2025-03-17T17:56:03Z

Michael at 19:52, 18 December 2024

2024-12-18T19:52:18Z

← Older revision		Revision as of 19:52, 18 December 2024
Line 9:		Line 9:
	*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>		*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>
	*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>		*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>
			*[[Malignant mesothelioma]].<ref name=pmid27066377>{{cite journal \|authors=Cheng X, Gou HF, Liu JY, Luo DY, Qiu M \|title=Clinical significance of serum CA125 in diffuse malignant mesothelioma \|journal=Springerplus \|volume=5 \|issue= \|pages=368 \|date=2016 \|pmid=27066377 \|pmc=4805673 \|doi=10.1186/s40064-016-1998-7 \|url=}}</ref><ref name=pmid9023557>{{cite journal \|authors=Bateman AC, al-Talib RK, Newman T, Williams JH, Herbert A \|title=Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression \|journal=Histopathology \|volume=30 \|issue=1 \|pages=49–56 \|date=January 1997 \|pmid=9023557 \|doi=10.1046/j.1365-2559.1996.d01-562.x \|url=}}</ref>

	==Positive/negative==		==Positive/negative==

Michael: /* Positive or negative */

2016-08-05T21:32:33Z

Positive or negative

← Older revision		Revision as of 21:32, 5 August 2016
Line 10:		Line 10:
	*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>		*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>

	==Positive or negative==		==Positive/negative==
	*[[Cholangiocarcinoma]] ~~+ve/~~-~~ve (~~30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal \| last1 = Higashi \| first1 = M. \| last2 = Yamada \| first2 = N. \| last3 = Yokoyama \| first3 = S. \| last4 = Kitamoto \| first4 = S. \| last5 = Tabata \| first5 = K. \| last6 = Koriyama \| first6 = C. \| last7 = Batra \| first7 = SK. \| last8 = Yonezawa \| first8 = S. \| title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. \| journal = Pathobiology \| volume = 79 \| issue = 2 \| pages = 101-6 \| month = \| year = 2012 \| doi = 10.1159/000335164 \| PMID = 22286058 }}</ref>).		*[[Cholangiocarcinoma]] - 30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal \| last1 = Higashi \| first1 = M. \| last2 = Yamada \| first2 = N. \| last3 = Yokoyama \| first3 = S. \| last4 = Kitamoto \| first4 = S. \| last5 = Tabata \| first5 = K. \| last6 = Koriyama \| first6 = C. \| last7 = Batra \| first7 = SK. \| last8 = Yonezawa \| first8 = S. \| title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. \| journal = Pathobiology \| volume = 79 \| issue = 2 \| pages = 101-6 \| month = \| year = 2012 \| doi = 10.1159/000335164 \| PMID = 22286058 }}</ref>.

	==Usually negative==		==Usually negative==

Michael: /* Positive or negative */

2016-08-05T21:32:02Z

Positive or negative

← Older revision		Revision as of 21:32, 5 August 2016
Line 11:		Line 11:

	==Positive or negative==		==Positive or negative==
	*[[Cholangiocarcinoma]] +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal \| last1 = Higashi \| first1 = M. \| last2 = Yamada \| first2 = N. \| last3 = Yokoyama \| first3 = S. \| last4 = Kitamoto \| first4 = S. \| last5 = Tabata \| first5 = K. \| last6 = Koriyama \| first6 = C. \| last7 = Batra \| first7 = SK. \| last8 = Yonezawa \| first8 = S. \| title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. \| journal = Pathobiology \| volume = 79 \| issue = 2 \| pages = 101-6 \| month = \| year = 2012 \| doi = 10.1159/000335164 \| PMID = 22286058 }}</ref>)		*[[Cholangiocarcinoma]] +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal \| last1 = Higashi \| first1 = M. \| last2 = Yamada \| first2 = N. \| last3 = Yokoyama \| first3 = S. \| last4 = Kitamoto \| first4 = S. \| last5 = Tabata \| first5 = K. \| last6 = Koriyama \| first6 = C. \| last7 = Batra \| first7 = SK. \| last8 = Yonezawa \| first8 = S. \| title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. \| journal = Pathobiology \| volume = 79 \| issue = 2 \| pages = 101-6 \| month = \| year = 2012 \| doi = 10.1159/000335164 \| PMID = 22286058 }}</ref>).

	==Usually negative==		==Usually negative==

Michael: /* Positive */

2016-08-05T21:31:57Z

Positive

← Older revision		Revision as of 21:31, 5 August 2016
Line 9:		Line 9:
	*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>		*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>
	*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>		*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>

			==Positive or negative==
			*[[Cholangiocarcinoma]] +ve/-ve (30 +ve of 63 cases<ref name=pmid22286058>{{Cite journal \| last1 = Higashi \| first1 = M. \| last2 = Yamada \| first2 = N. \| last3 = Yokoyama \| first3 = S. \| last4 = Kitamoto \| first4 = S. \| last5 = Tabata \| first5 = K. \| last6 = Koriyama \| first6 = C. \| last7 = Batra \| first7 = SK. \| last8 = Yonezawa \| first8 = S. \| title = Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. \| journal = Pathobiology \| volume = 79 \| issue = 2 \| pages = 101-6 \| month = \| year = 2012 \| doi = 10.1159/000335164 \| PMID = 22286058 }}</ref>)

	==Usually negative==		==Usually negative==

Michael: /* Positive */

2016-08-03T22:19:12Z

Positive

← Older revision		Revision as of 22:19, 3 August 2016
Line 5:		Line 5:

	==Positive==		==Positive==
	*[[~~Serous~~ carcinoma]].		*[[Ovarian carcinoma]] ~ 75% of cases.<ref name=pmid16224215/>
	*[[~~Breast~~ carcinoma]].		**[[Serous carcinoma of the ovary]] ~ 95% of cases.<ref name=pmid16224215/>
	*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>		*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>
	*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>		*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>

			==Usually negative==
			*[[Breast carcinoma]] ~15% of cases show weak focal positivity.<ref name=pmid16224215>{{Cite journal \| last1 = Tornos \| first1 = C. \| last2 = Soslow \| first2 = R. \| last3 = Chen \| first3 = S. \| last4 = Akram \| first4 = M. \| last5 = Hummer \| first5 = AJ. \| last6 = Abu-Rustum \| first6 = N. \| last7 = Norton \| first7 = L. \| last8 = Tan \| first8 = LK. \| title = Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. \| journal = Am J Surg Pathol \| volume = 29 \| issue = 11 \| pages = 1482-9 \| month = Nov \| year = 2005 \| doi = \| PMID = 16224215 }}</ref>

	==See also==		==See also==

Michael: /* Positive */

2016-08-03T22:11:53Z

Positive

← Older revision		Revision as of 22:11, 3 August 2016
Line 6:		Line 6:
	==Positive==		==Positive==
	*[[Serous carcinoma]].		*[[Serous carcinoma]].
			*[[Breast carcinoma]].
			*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid27093451>{{Cite journal \| last1 = Jiang \| first1 = K. \| last2 = Tan \| first2 = E. \| last3 = Sayegh \| first3 = Z. \| last4 = Centeno \| first4 = B. \| last5 = Malafa \| first5 = M. \| last6 = Coppola \| first6 = D. \| title = Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. \| journal = Appl Immunohistochem Mol Morphol \| volume = \| issue = \| pages = \| month = Apr \| year = 2016 \| doi = 10.1097/PAI.0000000000000368 \| PMID = 27093451 }}</ref>
			*[[Epithelioid sarcoma]] - reported.<ref name=pmid16740043>{{Cite journal \| last1 = Lee \| first1 = HI. \| last2 = Kang \| first2 = KH. \| last3 = Cho \| first3 = YM. \| last4 = Lee \| first4 = OJ. \| last5 = Ro \| first5 = JY. \| title = Proximal-type epithelioid sarcoma with elevated serum CA 125: report of a case with CA 125 immunoreactivity. \| journal = Arch Pathol Lab Med \| volume = 130 \| issue = 6 \| pages = 871-4 \| month = Jun \| year = 2006 \| doi = 10.1043/1543-2165(2006)130[871:PESWES]2.0.CO;2 \| PMID = 16740043 }}</ref>

	==See also==		==See also==

Michael: create

2016-08-03T22:04:49Z

create

New page

'''Cancer antigen 125''', abbreviated '''CA125''' and '''CA-125''', is a common [[immunostain]] and serum marker of disease.
It is also known as '''mucin 16''' and officially abbreviated '''MUC16'''.<ref name=pmid606154>{{OMIM|606154}}</ref><ref>URL: [http://www.ncbi.nlm.nih.gov/gene/94025 http://www.ncbi.nlm.nih.gov/gene/94025]. Accessed on: 3 August 2016.</ref>

It is elevated in the serum in [[ovarian cancer]] and mildly or moderately elevated in [[endometriosis]].

==Positive==
*[[Serous carcinoma]].

==See also==
*[[Immunohistochemistry]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]

← Older revision		Revision as of 17:56, 17 March 2025
Line 19:		Line 19:
	==See also==		==See also==
	*[[Immunohistochemistry]].		*[[Immunohistochemistry]].
			*[[Risk of malignancy index]].

	==References==		==References==